Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM

Blood

Volumn 114, Issue 8, 2009, Pages 1563-1575

  Alonso, Roberto ^a   López Guerra, Mónica ^a   Upshaw, Ramanda ^b   Bantia, Shanta ^b   Smal, Caroline ^c   Bontemps, Françoise ^c   Manz, Chantal ^d   Mehrling, Thomas ^d   Villamor, Neus ^a   Campo, Elias ^a   Montserrat, Emili ^a   Colomer, Dolors ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d Mundipharma International Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BENDAMUSTINE; BIM PROTEIN; CD38 ANTIGEN; DEOXYGUANOSINE TRIPHOSPHATE; FLUDARABINE; FORODESINE; PROTEIN KINASE ZAP 70; PROTEIN MCL 1; PROTEIN P53; PROTEIN P73; RITUXIMAB; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; DNA BINDING PROTEIN; DRUG DERIVATIVE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; ONCOPROTEIN; PURINE NUCLEOSIDE; PYRIMIDINONE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; VIDARABINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DISEASE COURSE; DNA DAMAGE; FEMALE; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CYCLOPHOSPHAMIDE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE PROTEINS; MITOCHONDRIA; NITROGEN MUSTARD COMPOUNDS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PURINE NUCLEOSIDES; PYRIMIDINONES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VIDARABINE;

EID: 70349567556     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-207654     Document Type: Article

References (50)

1. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 1998;91(9):3379-3389. (Pubitemid 28193890)
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-815.
3. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulinvariable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764-1775. (Pubitemid 36514707)
4. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98(9):2633-2639.
5. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916. (Pubitemid 32064784)
6. Bosch F, Ferrer A, Villamor N, et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008;14(1):155-161.
7. Hallek M, Eichhorst BF. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J. 2004;5(suppl 1):S20-S30.
8. Lamanna N, Jurcic JG, Noy A, et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol. 2009;27(4):491-497.
9. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(15):3383-3389.
10. Roué G, Lopez-Guerra M, Milpied P, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res. 2008;14(21):6907-6915.
11. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(27):4473-4479.
12. Packham G, Stevenson FK. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology. 2005;114(4):441-449.
13. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324-1337. (Pubitemid 46328466)
14. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10(3):456-459. (Pubitemid 26128784)
15. Bantia S, Miller PJ, Parker CD, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)-a novel potent and orally active immunosuppressive agent. Int Immunopharmacol. 2001;1(6):1199-1210. (Pubitemid 32434435)
16. Kicska GA, Long L, Horig H, et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad Sci U S A. 2001;98(8):4593-4598. (Pubitemid 32295021)
17. Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006;108(7):2392-2398. (Pubitemid 44497524)
18. Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol. 2003;3(6):879-887. (Pubitemid 36629453)
19. Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005;106(13):4253-4260. (Pubitemid 41775934)
20. Smal C, Vertommen D, Bertrand L, et al. Identification of in vivo phosphorylation sites on human deoxycytidine kinase: role of Ser-74 in the control of enzyme activity. J Biol Chem. 2006;281(8):4887-4893. (Pubitemid 43847750)
21. Smal C, Van den BG, Maerevoet M, et al. Positive regulation of deoxycytidine kinase activity by phosphorylation of Ser-74 in B-cell chronic lymphocytic leukaemia lymphocytes. Cancer Lett. 2007;253(1):68-73. (Pubitemid 46874730)
22. Ramadan S, Terrinoni A, Catani MV, et al. p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun. 2005;33(3):713-717.
23. Dicker F, Kater AP, Prada CE, et al. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood. 2006;108(10):3450-3457.
24. Amin AR, Paul RK, Thakur VS, Agarwal ML. A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, Concanavalin A. Cancer Res. 2007;67(12):5617-5621.
25. Van Den Neste E, Cardoen S, Offner F, Bontemps F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Int J Oncol. 2005;27(4):1113-1124.
26. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14(1):309-317.
27. Arpaia E, Benveniste P, Di Cristofano A, et al. Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med. 2000;191(12):2197-2208. (Pubitemid 30416365)
28. Zhu C, Johansson M, Permert J, Karlsson A. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines. J Biol Chem. 1998;273(24):14707-14711.
29. Moll UM, Zaika A. Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett. 2001;493(2-3):65-69.
30. Oka S, Ohno M, Tsuchimoto D, et al. Two distinct pathways of cell death triggered by oxidative damage to nuclear and mitochondrial DNAs. EMBO J. 2008;27(2):421-432. (Pubitemid 351161663)
31. Kao YY, Gianni D, Bohl B, Taylor RM, Bokoch GM. Identification of a conserved Rac-binding site on NADPH oxidases supports a direct GTPase regulatory mechanism. J Biol Chem. 2008;283(19):12736-12746.
32. Esteve JM, Mompo J, Garcia de la AJ, et al. Oxidative damage to mitochondrial DNA and glutathione oxidation in apoptosis: studies in vivo and in vitro. FASEB J. 1999;13(9):1055-1064.
33. Villamor N, Montserrat E, Colomer D. Cytotoxic effects of B lymphocytes mediated by reactive oxygen species. Curr Pharm Des. 2004;10(8):841-853.
34. Hussain SR, Cheney CM, Johnson AJ, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res. 2007;13(7):2144-2150.
35. Del Gaizo Moore V, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117(1):112-121. (Pubitemid 46048458)
36. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 2006;13(6):941-950.
37. Bertram C, Hass R. Cellular responses to reactive oxygen species-induced DNA damage and aging. Biol Chem. 2008;389(3):211-220. (Pubitemid 351329029)
38. Phillips AC, Vousden KH. E2F-1 induced apoptosis. Apoptosis. 2001;6(3):173-182.
39. Stevens C, La Thangue NB. A new role for E2F-1 in checkpoint control. Cell Cycle. 2003;2(5):435-437.
40. Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett. 2002;529(1):122-125.
41. Nicholson SA, Okby NT, Khan MA, et al. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res. 2001;61(14):5636-5643.
42. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene. 2008;27)40):5303-5314.
43. Irwin M, Marin MC, Phillips AC, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 2000;407(6804):645-648. (Pubitemid 30775377)
44. Essers MA, Weijzen S, de Vries-Smits AM, et al. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J. 2004;23(24):4802-4812. (Pubitemid 40069710)
45. Nowak K, Killmer K, Gessner C, Lutz W. E2F-1 regulates expression of FOXO1 and FOXO3a. Biochim Biophys Acta. 2007;1769(4):244-252.
46. Nakamura T, Sakamoto K. Forkhead transcription factor FOXO subfamily is essential for reactive oxygen species-induced apoptosis. Mol Cell Endocrinol. 2008;281(1-2):47-55.
47. Liu JW, Chandra D, Rudd MD, et al. Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS. Oncogene. 2005;24(12):2020- 2031. (Pubitemid 40516195)
48. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the proapoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol. 2000;10(19):1201-1204. (Pubitemid 30816681)
49. Sunters A, Fernandez de MS, Stahl M, et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 2003;278(50):49795-49805. (Pubitemid 37548813)
50. Essafi A, Fernandez de Mattos S, Hassen YA, et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene. 2005;24(14):2317-2329. (Pubitemid 40546691)